Crinecerfont is the first new treatment in 70 years for classic CAH and the only one that directly reduces excess ...

Innovent Biologics and Lilly expand collaboration agreement to commercialize BTK inhibitor, Jaypirca in Mainland China: San Francisco Tuesday, December 17, 2024, 11:00 Hrs [IST] I ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary ...

Arrowhead (ARWR) announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference, or ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary ...

The latest data from a new CDC report show a 700% plus increase in overdose deaths involving the fentanyl analog carfentanil ...

NewAmsterdam Pharma's obicetrapib demonstrates strong phase 3 results. Discover why NAMS stock could rise as further studies ...

Spruce Biosciences has trimmed the only drug from its pipeline in the wake of a second phase 2 failure this year, leaving the ...

The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.The ...

Hopes of a bright new future in stroke risk management in AF were dashed when asundexian failed against apixaban in the ...

Eptinezumab vs placebo significantly reduces acute headache medication in patients with migraine and those with medication overuse.

A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...